BioCentury | Nov 6, 2018
Company News

Management tracks: Audentes, Veloxis

...been interim CFO since Morten Marott stepped down from the position in September. Ophthalmology company SemaThera Inc....
BioCentury | Dec 15, 2017
Finance

Fewer, further

...Inc. (NASDAQ:VRTX) for undisclosed terms. AmorChem’s spinouts include cancer company SpecificiT Pharma Inc., ophthalmology play SemaThera Inc....
BioCentury | Jan 12, 2017
Emerging Company Profile

Looking beyond VEGF

...DME and DR. Molecular Partners AG has a VEGF inhibitor in Phase III for DME. SemaThera...
...the Quebec province, and Univalor, the tech transfer arm of Hôpital Maisonneuve-Rosemont . Ranger said SemaThera...
...inhibitors in ocular vasculopathies including DME, DR, and wet advanced macular degeneration (AMD). COMPANY PROFILE SemaThera Inc....
Items per page:
1 - 3 of 3
BioCentury | Nov 6, 2018
Company News

Management tracks: Audentes, Veloxis

...been interim CFO since Morten Marott stepped down from the position in September. Ophthalmology company SemaThera Inc....
BioCentury | Dec 15, 2017
Finance

Fewer, further

...Inc. (NASDAQ:VRTX) for undisclosed terms. AmorChem’s spinouts include cancer company SpecificiT Pharma Inc., ophthalmology play SemaThera Inc....
BioCentury | Jan 12, 2017
Emerging Company Profile

Looking beyond VEGF

...DME and DR. Molecular Partners AG has a VEGF inhibitor in Phase III for DME. SemaThera...
...the Quebec province, and Univalor, the tech transfer arm of Hôpital Maisonneuve-Rosemont . Ranger said SemaThera...
...inhibitors in ocular vasculopathies including DME, DR, and wet advanced macular degeneration (AMD). COMPANY PROFILE SemaThera Inc....
Items per page:
1 - 3 of 3